Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

CagriSema is a weekly injection combining semaglutide, which is the active ingredient in Wegovy and mimics the gut hormone ...

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their ...

(Wegovy is the version of semaglutide that’s available in the UK.) But tirzepatide (Mounjaro) has since been shown to pack more of a punch. “Semaglutide contains just one molecule, GLP-1 ...

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just weight loss Steve Christo/Corbis/Corbis/Getty ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...

In terms of its financial performance, Novo Nordisk's bread and butter are its therapies for type 2 diabetes (Ozempic) and obesity (Wegovy); both are the same molecule, semaglutide, which works by ...